Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697916 · ClinicalTrials.gov registry record · NA
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 15,076
- Enrollment target
NCT02697916 is a NA study that has completed, run by Duke University. The registered enrollment target is 15,076 participants.
The verdict
NCT02697916, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 15,076 participants
- Enrollment target
Study Summary
ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up will be 50 months. The purpose of the study is to identify the optimal dose of aspirin for secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD). The primary endpoint is a composite of all-cause death, hospitalization for MI, or hospitalization for stroke. The primary safety endpoint is hospitalization for major bleeding with an associated blood product transfusion.
Interventions
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,076 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697916
The ClinicalTrials.gov registry entry for NCT02697916 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15,076 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aspirin is the first listed.
NCT02697916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697916 about?
NCT02697916 is a clinical study titled "Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term". ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up will be 50 months. The purp...
What is the current status of trial NCT02697916?
This trial is currently completed. It is a NA study. The enrollment target is 15,076 participants. The study started on 2016-04. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT02697916?
The interventions under investigation include: aspirin (DRUG).
Who is sponsoring clinical trial NCT02697916?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.